Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
OP has been using alfatradiol and a mix of rosemary, peppermint, and jojoba oils for hair loss, with inconsistent dermapen sessions. They plan to add topical finasteride at 0.025% later.
The user has been using oral finasteride and minoxidil nightly, dutasteride twice a week, microneedling weekly, and pyripure nightly since April. They are seeking opinions on their hair regrowth progress, noting no slick bald areas but some miniaturized blonde hairs.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
The conversation is about finding shampoos with Piroctone Olamine in the US for itch relief, as the user has not found relief with Keto shampoo, oral Dutasteride, and oral Minoxidil. Users suggest alternatives like Neutrogena T/Gel and online options, but note availability and price issues.
A 21-year-old male used 1mg of finasteride since March with no results and suspects a scalp fungus due to pimples and burning sensations. He is seeking advice on treating the potential fungus.
RU58841 for hair loss, discussing sources, application methods, and carriers like PG + ethanol or liquid minoxidil. Users share experiences with premixed solutions and powder forms, noting price differences and storage importance.
The post expresses frustration over the unavailability of pure topical finasteride in India despite the developed pharma industry. The user seeks advice on making it at home and its effectiveness.
RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.
Finasteride can cause pelvic or urethral discomfort for some users. Reducing the dose to 0.25 mg on Mondays, Wednesdays, and Fridays is being considered as a potential solution.
The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.
RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.
RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.
RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
The user has been using finasteride, minoxidil, and needling for 11 months with limited progress and plans to add sulforaphane for 3 months. Another user suggested trying Procyanidin B2 for better results.
User added RU and pyrilutamide for hair growth and noticed more baby hairs. Others suggest sticking with fin and min, while some discuss the user's self-image and hair loss severity.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
The user has been taking finasteride for nearly two months and has noticed an increased urge to urinate with slight discomfort. They are questioning if this side effect is temporary.